Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katelyn Brown

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Proceedings (Baylor University. Medical Center)|April 9, 2019
Comparison of reflex, resistance training, and core activities using change in blood pressure over time after spontaneous coronary artery dissectionKatelyn Brown, Jenny Adams, Peter A McCullough
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. ReplyJuan P Frías, Laura Fernández Landó, Katelyn Brown
Disability and Rehabilitation. Assistive Technology|March 26, 2019
Creating a digital memory notebook application for individuals with mild cognitive impairment to support everyday functioningNisha Raghunath, Jessamyn Dahmen, Katelyn Brown, et al.
The Clinical Neuropsychologist|March 13, 2024
Naturalistic assessment of everyday multitasking in Parkinson's disease with and without mild cognitive impairmentMaureen Schmitter-Edgecombe, Katelyn Brown, Reanne Cunningham Chilton, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Use of Proprietary Names by Prescribers for Generic ProductsVicky Borders-Hemphill, Irene Z Chan, Katelyn Brown, et al.
Cardiovascular Diabetology|March 25, 2023
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programIldiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Journal of Alzheimer'S Disease : JAD|November 15, 2021
Partnering a Compensatory Application with Activity-Aware Prompting to Improve Use in Individuals with Amnestic Mild Cognitive Impairment: A Randomized Controlled Pilot Clinical TrialMaureen Schmitter-Edgecombe, Katelyn Brown, Catherine Luna, et al.
The Lancet. Diabetes & Endocrinology|April 25, 2022
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trialTadej Battelino, Richard M Bergenstal, Angel Rodríguez, et al.
Diabetes, Obesity & Metabolism|February 10, 2017
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutideCarlos Alatorre, Laura Fernández Landó, Maria Yu, et al.
Patient Preference and Adherence|March 29, 2023
The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 DiabetesHeather L Gelhorn, Beatrice Osumili, Katelyn Brown, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Proceedings (Baylor University. Medical Center)|April 9, 2019
Comparison of reflex, resistance training, and core activities using change in blood pressure over time after spontaneous coronary artery dissectionKatelyn Brown, Jenny Adams, Peter A McCullough
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. ReplyJuan P Frías, Laura Fernández Landó, Katelyn Brown
Disability and Rehabilitation. Assistive Technology|March 26, 2019
Creating a digital memory notebook application for individuals with mild cognitive impairment to support everyday functioningNisha Raghunath, Jessamyn Dahmen, Katelyn Brown, et al.
The Clinical Neuropsychologist|March 13, 2024
Naturalistic assessment of everyday multitasking in Parkinson's disease with and without mild cognitive impairmentMaureen Schmitter-Edgecombe, Katelyn Brown, Reanne Cunningham Chilton, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Use of Proprietary Names by Prescribers for Generic ProductsVicky Borders-Hemphill, Irene Z Chan, Katelyn Brown, et al.
Cardiovascular Diabetology|March 25, 2023
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programIldiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Journal of Alzheimer'S Disease : JAD|November 15, 2021
Partnering a Compensatory Application with Activity-Aware Prompting to Improve Use in Individuals with Amnestic Mild Cognitive Impairment: A Randomized Controlled Pilot Clinical TrialMaureen Schmitter-Edgecombe, Katelyn Brown, Catherine Luna, et al.
The Lancet. Diabetes & Endocrinology|April 25, 2022
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trialTadej Battelino, Richard M Bergenstal, Angel Rodríguez, et al.
Diabetes, Obesity & Metabolism|February 10, 2017
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutideCarlos Alatorre, Laura Fernández Landó, Maria Yu, et al.
Patient Preference and Adherence|March 29, 2023
The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 DiabetesHeather L Gelhorn, Beatrice Osumili, Katelyn Brown, et al.
Pageof 2